ImmunityBio, Inc. (IBRX)
IBRX: What Anktiva's Bladder Data Says About 2026 Sales
ImmunityBio heads into 2026 riding Anktiva growth, but upcoming bladder trial data and broader use in earlier care will be key to sustaining momentum.
Is IBRX Priced for Perfection at Nearly 28x Forward Sales?
ImmunityBio IBRX has delivered a stunning rerating in 2026. After a move like this, investors often stop debating the story and start debating the price.
What Makes ImmunityBio (IBRX) a New Buy Stock
ImmunityBio (IBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Reframing ImmunityBio: The Long-Term Platform Opportunity Beyond Anktiva
ImmunityBio is transitioning from a single-product biotech to a potential multi-billion-dollar oncology and cell therapy platform company. Anktiva's commercial momentum is strong, with 1Q26 revenue up 168% YoY and FY25 revenue reaching $113 million, supported by guideline inclusion and global approvals. The Leonardo platform is central to the long-term bull case, aiming to industrialize NK-cell therapies through scalable manufacturing and hospital partnerships.
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results
ImmunityBio stock jumps 7% as Q1 2026 revenues surge 168% on strong Anktiva uptake, with expanding approvals and pipeline progress boosting momentum.
IBRX Responds to FDA Warning Over Misleading Cancer Drug Claims
ImmunityBio responds to an FDA warning over misleading Anktiva claims and outlines compliance fixes as strong sales growth and expansion efforts remain in focus.
ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?
IBRX and MRNA hinge on single-drug success, but pipeline depth, growth plans and risks set them apart in the race for biotech upside.
Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report?
ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock?
IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims
ImmunityBio stock sinks 21% after the FDA flags misleading claims on cancer drug Anktiva, citing exaggerated benefits and inadequate risk disclosures.
ImmunityBio stock price crash: buy the dip or sell the rip?
ImmunityBio Inc (NASDAQ: IBRX) is under immense pressure on March 24 after the US Food and Drug Administration (FDA) issued a scathing warning letter over the firm's promotional tactics. Investors bailed on IBRX as regulators alleged the company and its billionaire founder, Dr. Patrick Soon-Shiong, used a TV ad and a high-profile podcast to make “false or misleading” claims about Anktiva.
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
IBRX stock jumps after China approves Anktiva combo therapy for bladder cancer, marking its first Asia nod and expanding global reach to 34 markets.
Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?
ImmunityBio bets on Anktiva label expansion to drive growth, but intense Big Pharma competition and premium valuation raise questions about its next phase.
